Biotage AB (publ)
Biotage AB (publ) (BITGF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bitgf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Biotage AB (publ) (BITGF) measures how much investors pay for each dollar of the company's trailing earnings. BITGF's current PE ratio of 70.33x is calculated by dividing its stock price of $15.01 by its TTM earnings per share of $2.04. +35.3% elevated vs 5Y avg 52.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 18 fiscal years · Front-end computedMinQ1 · 25%33.0x
MedianQ3 · 75%241.1x
Max
At 70.33x, BITGF's current P/E is higher than in 89% of its annual fiscal year readings over the past 18 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biotage AB (publ)You BITGF | $1.2B | 70.33x | +51.2% | $2.04 |
 Biotest AG BTTAY | $943M | 66.05x | +42.0% | $0.35 |
 CompuGroup Medical SE & Co. KGaA CMPUY | $1.2B | 33.34x | -28.3% | $0.67 |
 CompuGroup Medical SE & Co. KGaA CMPVF | $1.7B | 52.49x | +12.8% | $0.55 |
 Drägerwerk AG & Co. KGaA DGWPF | $1.4B | 8.23x | -82.3% | $7.44 |
 Karo Pharma AB (publ) KARBF | $1.5B | N/A | — | — |
 Kaken Pharmaceutical Co., Ltd. KKPCF | $1.0B | 72.51x | +55.8% | $56.91 |
Industry Average 5 peers with valid PE | — | 46.53x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 46.23x | $3.55 | +27.4% | |
2023-12-31 FY2023 | 36.28x | $3.33 | -16.7% | |
2022-12-31 FY2022 | 43.56x | $4.06 | -48.6% | |
2021-12-31 FY2021 | 84.80x | $3.14 | +73.1% | |
2020-12-31 FY2020 | 48.99x | $2.68 | +22.4% | |
2019-12-31 FY2019 | 40.04x | $2.87 | -3.7% | |
2018-12-31 FY2018 | 41.56x | $2.59 | +9.6% | |
2017-12-31 FY2017 | 37.91x | $2.14 | +27.2% | |
2016-12-31 FY2016 | 29.79x | $1.43 | +114.6% | |
2015-12-31 FY2015 | 13.88x | $1.13 | +11.3% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biotage AB (publ) (BITGF) measures how much investors pay for each dollar of the company's trailing earnings. BITGF's current PE ratio of 70.33x is calculated by dividing its stock price of $15.01 by its TTM earnings per share of $2.04.
Frequently asked questions
BITGF pe ratio · 6 questionsBITGF's current PE ratio is 70.33x as of 2026-06-08, based on a stock price of $15.01 and TTM EPS of $2.04. Data sourced from Financial Modeling Prep via BITGF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biotage AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08